Share This

Public company info - Mingyuan Medicare Development Co. Ltd. , 00233.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Mingyuan Medicare Development Co. Ltd., 00233.HK - Company Profile
Chairman Lam Ping Cheung
Share Issued (share) 4,384,000,000
Par Currency Hong Kong Dollar
Par Value 0.05
Industry Medical Equipment & Services
Corporate Profile Business Summary: The group is principally engaged in manufacture and trading of protein chips and related equipments; provision of cervical cancer care services and operation of Shanghai Woman and Child Healthcare Hospital of Hong-Kou District, Shanghai, the PRC. Performance for the year: The division recorded total sales of HK$66.00 million (2017: HK$48.82 million). Business Review： As at the date of this Announcement, the Board is still in the process of getting back the control over the Group’s two key subsidiaries, Shanghai HealthDigit and SHMY Biochip, and is unable to access to their books and records. As a result, the balances relating to these two subsidiaries brought forward from 31 December 2013 were derecognized and the financial effects were charged to the consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2014 (“Derecognition”). Derecognition results loss of HK$804.5 million for the financial year 2014. After the Derecognition of the above subsidiaries, the Group only maintained Health Care Division which sells HPV DNA testing kits to female patients at hospital nationwide. The division recorded total sales of HK$66.00 million (2017: HK$48.82 million). Prospects: The Company has continued to carry on its principal business in manufacturing and trading of HPV chips and related equipment through Genetel Pharmaceuticals (Shenzhen) Company Limited in PRC. Shareholders may refer to the announcements made by the Company on 10 August 2018, 15 November 2018, 11 February 2019 and 2 May 2019 respectively on the updates on trading suspension. The Company will endeavor to publish all outstanding financial results and demonstrate to the Stock Exchange that all the resumption conditions have been fulfilled and to the SFC that its concerns have been properly addressed.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.